

AMENDMENTS TO THE CLAIMS

1. (currently amended) An antibody, comprising the V_H domain of the antibody produced by the hybridoma of ATCC deposit number CRL 8001, wherein the cysteine at position H100A of said V_H domain is substituted with a ~~polar amino acid~~ serine, wherein said position H100A is according to the Kabat numbering system, wherein said antibody comprises the amino acid sequence depicted by SEQ ID NO:2.

Claims 2-3 (cancelled).

4. (currently amended) A method for the production of the antibody according to claim 1, characterized by the steps of:

- a) obtaining mRNA from freshly subcloned hybridoma cells of ATCC deposit number CRL 8001 and transcription into cDNA,
- b) amplifying the cDNA coding for the variable domains of the light and heavy chains by means of PCR,
- c) cloning of the cDNA obtained in b) into a vector adapted for site-specific mutagenesis,
- d) introducing a mutation to the cDNA, wherein said mutation is the substitution of a cysteine with a ~~polar amino acid~~ serine at position H100A of the V_H domain according to the Kabat numbering system, and
- e) inserting the mutated cDNA obtained in e) ~~d~~ in an expression vector and expression in a suitable expression system.

5. (previously presented) The method according to claim 4, wherein the amplifying of step b) uses primers having the nucleotide sequences depicted by SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10 and SEQ ID NO:11 .

6. (previously presented) The method according to claim 4, wherein the vector used in step c) is pCR-Skript SK(+).

7. (previously presented) The method according to claim 4, wherein said cloning uses a primer comprising the sequence depicted by SEQ ID NO: 7.

Claim 8 (cancelled).

9. (previously presented) The method according to claim 4, wherein the expression takes place in XL1-Blue *E. coli* cells.
12. (previously presented) The method according to claim 5, wherein the vector used in step c) is pCR-Skript SK(+).
13. (previously presented) The method according to claim 5, wherein said cloning uses a primer comprising the sequence depicted by SEQ ID NO: 7.
14. (previously presented) The method according to claim 6, wherein said cloning uses a primer comprising the sequence depicted by SEQ ID NO: 7.

Claims 15-18 (cancelled).

19. (previously presented) The method according to claim 5, wherein the expression takes place in XL1-Blue *E. coli* cells.
20. (previously presented) The method according to claim 6, wherein the expression takes place in XL1-Blue *E. coli* cells.
21. (previously presented) The method according to claim 7, wherein the expression takes place in XL1-Blue *E. coli* cells.

Claim 22 (cancelled).

23. (previously presented) A peptide comprising the amino acid sequence depicted by SEQ ID NO:2.
24. (previously presented) An antibody comprising the peptide according to Claim 23.
25. (previously presented) A single-chain antibody comprising the peptide according to Claim 23.
26. (previously presented) A bispecific antibody comprising the peptide according to Claim 23.

Claim 27 (cancelled).

28. (previously presented) The antibody of claim 1, wherein said antibody is a

monoclonal antibody.

Claim 29 (cancelled).